Manchester, UK, 24th January 2017 –
Elucigene Diagnostics, developer and distributor of leading prenatal and human genetics diagnostics have today partnered with Genomax Technologies, to bring Elucigene leading brands such as CFEU2v1 and QST*R, to Singapore, Malaysia and Thailand.
Genomax Technologies (Singapore), founded in 2003, provide life science and medical institutions in Singapore, Malaysia, and Thailand with high quality innovative products and services, enabling customers to remain at the forefront of medical technology. All products and services are supported by outstanding technical assistance and customer service. The addition of the Elucigene range of products will further develop Genomax Technologies growing diagnostics offering, particularly in the field of prenatal screening and genetic diagnosis.
Dr Mark Street-Docherty, Sales and Marketing Director of Elucigene Diagnostics says “We are delighted to be partnering with Genomax to further expand Elucigene Diagnostics global reach, and provide our offering to new customers in one of the world most technologically advanced regions.”
“Elucigene Diagnostics’ range of high-quality and innovative test kit for rapid aneuploidy analysis and reproductive health address the need of the rapid growing market for prenatal & human genetics testing in South East Asia. Clinical laboratories here demand highest quality products for their test service, Elucigene’ s CE-IVD labelled products meets their requirement” says Lin Sheng Wong, Managing Director of Genomax Technologies.
Elucigene products will be offered through the partnership from January 2017, interested parties should contact email@example.com for more detailed information.
About Elucigene Diagnostics Ltd
Elucigene Diagnostics (Manchester, UK) is a leading molecular diagnostics design, manufacture, and distribution company, offering a suite of in vitro diagnostic CE marked products for prenatal, rare disease, and infertility genetic diagnosis. Elucigene aims to provide customers with products that enable clarity of clinical utility without complexity in sample processing and analysis.